CRBP

Corbus Pharmaceuticals Holdings, Inc.

50.49 USD
+0.39 (+0.78%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Corbus Pharmaceuticals Holdings, Inc. stock is up 9.95% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 June’s closed higher than May. In the last 8 Unusual Options Trades, there were 6 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Apr 14:08 21 Jun, 2024 40.00 CALL 80 301
22 Apr 16:14 17 May, 2024 35.00 CALL 70 101
23 May 19:29 21 Jun, 2024 40.00 CALL 50 410
24 May 18:55 20 Dec, 2024 60.00 CALL 90 0
28 May 18:42 21 Jun, 2024 40.00 CALL 43 460
03 Jun 14:04 21 Jun, 2024 45.00 PUT 100 57
11 Jun 14:09 21 Jun, 2024 50.00 PUT 83 200
12 Jun 13:49 20 Dec, 2024 60.00 CALL 100 100

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus. CRB-601, an anti-integrin monoclonal antibody (mAb) that inhibits the activation of transforming growth factor ß (TGFß)

  • RBC Capital
    Tue Jun 11, 08:15
    buy
    confirm
  • Oppenheimer
    Mon Jun 3, 08:22
    buy
    confirm